Great Valley Advisor Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Great Valley Advisor Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,754	Closed	-$309K	–	833
2024 Q2	$309K	Sell	3,754 -533	-12%	-$44.4K	0.01%	636
2024 Q1	$374K	Sell	4,287 -1,028	-19%	-$92K	0.01%	556
2023 Q4	$512K	Sell	5,315 -445	-8%	-$39.4K	0.02%	455
2023 Q3	$510K	Hold	5,760	–	–	0.02%	430
2023 Q2	$499K	Sell	5,760 -235	-4%	-$22.1K	0.02%	446
2023 Q1	$583K	Sell	5,995 -19	-0.3%	-$1.97K	0.03%	407
2022 Q4	$622K	Sell	6,014 -92	-2%	-$8.64K	0.03%	403
2022 Q3	$518K	Sell	6,106 -3,828	-39%	-$341K	0.03%	412
2022 Q2	$823K	Buy	9,934 +5,944	+149%	+$473K	0.05%	336
2022 Q1	$314K	Buy	3,990 +1,525	+62%	+$128K	0.02%	479
2021 Q4	$218K	Buy	+2,465	New	+$203K	0.01%	558

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Great Valley Advisor Group's BMRN Position: Q3 2024 in Review

Great Valley Advisor Group sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 3,754 shares — an estimated $309K sold.

Great Valley Advisor Group first reported a position in BMRN in Q4 2021 and held it in 11 quarters. The position peaked at $823K in Q2 2022. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Great Valley Advisor Group reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Great Valley Advisor Group sold 3,754 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $309K.
Great Valley Advisor Group first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 11 quarters.
Great Valley Advisor Group's BioMarin Pharmaceuticals position peaked at $823K in Q2 2022.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Great Valley Advisor Group's 13F filing for Q3 2024, filed 12 Nov 2024.